Late Effects in Survivors of Pediatric Medulloblastoma: A Comprehensive Review.
Por:
Ana Carolina Izurieta Pacheco, Ramaswamy V, Tsang DS, Rutka J, Wasserman J, Guger S, Weidman DR, Nathan PC, Scheinemann K and Bennett J
Publicada:
1 ene 2026
Ahead of Print:
30 oct 2025
Resumen:
Medulloblastoma (MB) treatment has advanced significantly with the integration of molecular subgrouping, enabling more precise risk stratification and tailored therapies. While survival outcomes have improved, long-term treatment-related morbidity remains a significant challenge. This review summarizes the spectrum of late effects experienced by survivors of pediatric MB. Special attention is placed on the impact of proton therapy in reducing treatment toxicity. As therapeutic paradigms continue to evolve, historical data may no longer accurately reflect the toxicity profile of contemporary treatments. Therefore, prospective, molecularly annotated survivorship studies are needed to determine whether recent advances in treatment will lead to sustained improvements in health, functionality, and quality of life.
Filiaciones:
Ana Carolina Izurieta Pacheco:
Department of Pediatrics, Division of Pediatric Hematology/Oncology, The Hospital for Sick Children, Toronto, ON, Canada
Oncology Department, Pediatric Cancer Center Barcelona, Hospital Sant Joan de Déu, Barcelona, Spain
Ramaswamy V:
Department of Pediatrics, Division of Pediatric Hematology/Oncology, The Hospital for Sick Children, Toronto, ON, Canada
Tsang DS:
Department of Radiation Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
Rutka J:
Department of Surgery, Division of Neurosurgery, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada
Wasserman J:
Department of Pediatrics, Division of Endocrinology, The Hospital for Sick Children, Toronto, ON, Canada
Guger S:
Department of Psychology, The Hospital for Sick Children, Toronto, ON, Canada
Weidman DR:
Department of Pediatrics, Division of Pediatric Hematology/Oncology, The Hospital for Sick Children, Toronto, ON, Canada
Department of Radiation Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
Nathan PC:
Department of Pediatrics, Division of Pediatric Hematology/Oncology, The Hospital for Sick Children, Toronto, ON, Canada
Scheinemann K:
Division of Oncology-Hematology, Children's Hospital of Eastern Switzerland, St Gallen, Switzerland
Faculty of Health Sciences and Medicine, University of Lucerne, Lucerne, Switzerland
Bennett J:
Department of Pediatrics, Division of Pediatric Hematology/Oncology, The Hospital for Sick Children, Toronto, ON, Canada
Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
Bronze
|